Research ExplorerJournalsPSYCHOPHARMAKOTHERAP Publications

PSYCHOPHARMAKOTHERAP - Psychopharmakotherapie

1 - 11 out of 11Page size: 50

Publications

  1. 2021

  2. Ressourcennutzung in einer nichtinterventionellen Studie zur Anwendung von Aripiprazol-Depot

    Schöttle, D., Janetzky, W., Lüdecke, D. & Wiedemann, K., 2021, In: PSYCHOPHARMAKOTHERAP. 2021, 28, p. 210-214 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. 2020

  4. Aripiprazol-Depot für ambulante Patienten mit Schizophrenie: Patientenzentrierte Outcomes einer nichtinterventionellen Studie

    Schöttle, D., Janetzky, W., Beck, E., Correll, C. U. & Wiedemann, K., 10.2020, In: PSYCHOPHARMAKOTHERAP. 27, 5, p. 236-646 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  5. Cannabis in der Neurologie

    Mainka, T. & Buhmann, C., 2020, In: PSYCHOPHARMAKOTHERAP. 2020, 27, p. 122-127

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  6. 2019

  7. Nichtinterventionelle Studie zur Wirkung von Aripiprazol-Depot bei Patienten mit Schizophrenie unter Routinebedingungen in Deutschland

    Schöttle, D., Janetzky, W., Beck, E., Correll, C. U. & Wiedemann, K., 2019, In: PSYCHOPHARMAKOTHERAP. p. 219-26 26.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2018

  9. Internet-basierte Interventionen bei Depressionen: Evidenz und Stellenwert in der Praxis.

    Krieger, T., Klein, J. P., Moritz, S. & Berger, T., 2018, In: PSYCHOPHARMAKOTHERAP. 25, p. 2-8

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. 2016

  11. Langzeittherapie in der Schizophrenie

    Lambert, M., Ruppelt, F., Rohenkohl, A., Karow, A., Gallinat, J. & Wiedemann, K., 2016, In: PSYCHOPHARMAKOTHERAP. 23, p. 58-66

    Research output: SCORING: Contribution to journal › Newspaper articles › Transfer

  12. 2014

  13. Rationale und Zielsetzung der medikamentösen Therapie der Schizophrenie

    Sina, K., Kuhn, J. & Wiedemann, K., 2014, In: PSYCHOPHARMAKOTHERAP. 21, 3, p. 85-95

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. 2002

  15. Subjective well-being under neuroleptic treatment - relevant for the psychopharmacotherapy of schizophrenic patients?

    Lambert, M., Schimmelmann, B. G., Haasen, C. & Naber, D., 2002, In: PSYCHOPHARMAKOTHERAP. 2, p. 53-59

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  16. 2000

  17. Treatment resistance in schizophrenic patients - actual standards.

    Lambert, M., Moritz, S., Bender, S., Krausz, M. & Naber, D., 2000, In: PSYCHOPHARMAKOTHERAP. 8, p. 2-17

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  18. 1999

  19. Olanzapine - an atypical antipsychotic in the treatment of schizophrenia.

    Lambert, M., Perro, C., Holzbach, R., Krausz, M. & Naber, D., 1999, In: PSYCHOPHARMAKOTHERAP. 2, p. 38-52

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  20. Optimising treatment of schizophrenic patients with atypical neuroleptics.

    Lambert, M., Moritz, S. & Naber, D., 1999, In: PSYCHOPHARMAKOTHERAP. 3, p. 42-54

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research